IFIH1 and dermatomyositis: According to previous studies, the mortality of RP-ILD related to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (MDA5+ DM) in the first year ranged from 34.8% - 80% (3, 6, 7).